Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples

Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.

price-ascending: candidates are ordered by the listed price of the operation, with no managed-first preference applied. Unlike /v1/apis, this surface does not rank Apiosk-settled listings above federated ones — a comparison that reorders on commercial grounds is not a comparison. Pass sort=managed_first for the catalog's ordering.

Compared: listed price, settlement rail and input compatibility. Not measured yet: latency, reliability, result quality, and provider terms such as rate limits, jurisdiction and licensing.